JW Shinyak, a subsidiary of JW Holdings, said it started marketing J-retal CR, an antithrombotic medication, from Monday.

The drug is an antithrombotic agent that inhibits platelet aggregation and inhibits blood clot production. It is useful in improving the symptoms of chronic arterial obstruction such as arteriosclerosis, cerebral infarction, Burger's disease, diabetic peripheral angiopathy, and recurrence of cerebrovascular diseases such as cerebral infarction.

Unlike conventional immediate-release products where patients had to take two a day, the product was developed as a sustained-release product, which requires patients to take only one pill a day. The treatment has also improved gastrointestinal bleeding side effects compared to aspirin preparations.

"As population aging progresses rapidly, the antithrombotic market is expanding," a company official said. "We will actively market the drug to help prevent cardiovascular disease and improve the quality of life for patients."